Newsletter · · Ashutosh Agarwal

Healthcare Policy - Week of June 20, 2026: 340B Is the Battle; IRA Is the Footnote

Healthcare policy newsletter for the week of June 20, 2026 (coverage window June 13–20). The hand-to-hand drug-pricing fight has moved from IRA timelines to 340B, where Lilly is sending hospitals five-day ultimatums and AbbVie is in federal court to narrow the patient definition, while managed care gets squeezed by Medicaid churn and a UnitedHealth billing probe.

Healthcare Policy: Drug Pricing, IRA & Managed Care

Week of June 13–20, 2026: 340B Is the Battle; IRA Is the Footnote

Intro

If you came into this week braced for fresh IRA fireworks, you were looking at the wrong front. The negotiation timelines and Most-Favored-Nation letters are still the macro story, but the actual hand-to-hand combat has moved to 340B, where Eli Lilly is now sending hospitals five-day ultimatums and AbbVie has dragged the patient definition into federal court. Meanwhile the managed-care side of the ledger is quietly grinding: Medicaid work requirements are about to start shaking people off the rolls, and UnitedHealth's Medicare Advantage billing remains under a federal microscope. Here's what the tape actually said.

TL;DR

  • 340B went from threat to action. Lilly is sending ultimatum letters giving hospitals five business days to hand over claims data or lose discounts; AbbVie is in D.C. District Court trying to narrow the patient definition. This is the live policy fight of the week, and it's being run by manufacturers, not Congress.
  • MFN/IRA is loud but the nominal Part D exposure is small, one estimate pegs it at ~2% of Part D spend after exclusions, and the real battle is heading to the courts over CMS's authority, not to the statute books.
  • Managed care is being squeezed from two sides: Medicaid work-requirement churn and the ACA enhanced-subsidy sunset on the membership line, and a DOJ probe plus brutal prior-auth overturn data on the credibility line.

What's New

1. Lilly's 340B ultimatum letters are out, and a trade group is calling them unlawful. On Monitor Mondays, Maureen Testoni, CEO of 340B Health (operator/insider), said Lilly "began sending ultimatum letters to selected hospitals. Those letters told hospitals they had just five business days to begin submitting claims data to the company or risk losing 340B pricing on Lilly drugs." Her legal read: "The 340B statute requires drug companies to provide 340B discounted pricing to eligible hospitals. It does not require hospitals to hand over large volumes of patient data... If Lilly succeeds... other drug companies will have every incentive to adopt similar policies." Why it matters: this is the data-for-discount standoff going from posturing to enforcement, and the contagion risk across manufacturers is the whole point.

2. AbbVie is asking a federal court to shrink the 340B patient definition. On 340B Unscripted, Mark Oginshushi, a K&L Gates healthcare attorney/pharmacist (operator/insider), explained AbbVie is "asking a federal court, the D.C. District Court, to adopt their reading as the best reading", a test where a script qualifies only if "the care is recent, setting a temporal limit of 12 months." Co-host Rob DeHuby (operator/insider) flagged the manufacturers' downside: aggressive moves "could be a violation of the pharmaceutical pricing agreement and risk Lilly no longer having access to Medicaid formulary." Why it matters: AbbVie's 12-month definition is far tighter than the 24-month and multi-year readings hospitals use, if a court buys it, eligible volume shrinks structurally.

3. The reform crowd is reframing 340B as a hidden tax expenditure. On DC EKG, host Joe Grogan, former White House Domestic Policy Council director (operator/insider), and economist Ike Brannan argued lawmakers "see the 340B program as a net $60 billion plus subsidy to the hospitals that cost the federal government nothing," and that putting it on the official tax-expenditure list is the play: "whenever people on either side of the aisle are trying to figure out how do we balance the budget... that's the list they start from first." Brannan's provocation: "We solve this problem with the Affordable Care Act... And this thing is just superfluous now." Why it matters: this is how a program gets onto a pay-for menu, watch for it surfacing in future budget math.

4. MFN: 17 deals signed, but the exposure math is smaller than the headlines. On Pathfinders in Biopharma, Capstone analysts Will Humphrey and Hunter Hammond (pundits) noted "the president sent out 17 letters to 17 manufacturers. He has 17 deals", paired with 100% tariffs phased in for large companies (end of July) and smaller ones (end of September). But on the mandatory Part D/Part B models: "you get to around 8% of Part D spend that would be exposed... So we're talking about 2% of Part D spend. The models obviously are scary... but the nominal exposure is actually quite low." Their forecast: "The next battle... are going to be in the courts... their authority to do this is going to be challenged on constitutional grounds." Why it matters: the bark-vs-bite gap matters for how much of the MFN scare is actually in pharma numbers. (Panel recorded mid-May, published this week.)

5. The GLP-1 access map just shifted, and CVS blinked. On CareTalk, consultant David Williams (pundit) noted "CVS Caremark is restoring coverage of Zepbound, reversing a formulary decision from last summer," and walked through the new federal backstop: "the Medicare-GLP-1 bridge, which is going to cover these drugs starting in July through the end of 2027 with Medicare footing the bill. Only 13 states cover GLP-1s for obesity [in Medicaid]. And that's actually down from 16 a year ago." On Pathfinders, Capstone added that CMS "decided to uphold their end of the bargain with Lilly and Novo... CMS owns all of the risk," likening it to "a European HTA-style model." Why it matters: a federal payer is now pulling GLP-1 demand through Part D while a major PBM reverses an exclusion, both directionally positive for LLY/NVO volume, with the pricing mechanism worth watching.

The Debate

On 340B, both sides are real. Hospitals (operators): the statute is a one-way obligation, manufacturers must discount; nothing requires hospitals to surrender patient claims data as a condition, so Lilly's ultimatum is coercion dressed as compliance. Manufacturers/reformers: the program has metastasized into a ~$60B+ transfer with weak guardrails on who counts as a "patient," contract-pharmacy sprawl invites diversion, and, per the DC EKG framing, the ACA arguably made the original 1992 rationale obsolete. The tape genuinely supports both; the question a court (and possibly HRSA) will referee is whether data demands are a legitimate integrity tool or an unlawful end-run.

On IRA/MFN, the debate is scope, not direction. Bears: convergence of IRA timelines, MFN reference pricing now reaching into Medicaid, and tariff threats compresses NPVs. Lumanity's Steve Mather (pundit) said the IRA "set a nine year window for small molecules before pricing negotiations... There's a slightly longer term frame for biologics. That's 13 years... it fundamentally alters NPV calculations," and described a top-25 company that "chose to... shift the balance more towards complex therapies." Skeptics: the mandatory-model exposure is ~2% of Part D spend, the legal foundation is shaky, and much of MFN may die in litigation. Both are on the record this week.

The Names in Play

  • LLY: at the center of the 340B fight (ultimatum letters) and a winner on the GLP-1 bridge/CVS reversal; the Medicaid-formulary risk if HRSA pushes back is the offset.
  • ABBV: plaintiff trying to legally narrow 340B; a win shrinks discounted volume industry-wide.
  • UNH: Telltales (AI-hosted, pundit) framed the setup bluntly: "you're not buying 14 times earnings, you're buying 14 times a number that's under subpoena. The free cash flow comes from Medicare Advantage billing, and a federal prosecutor is now asking whether that billing was fraudulent." Sell side is "openly split... a coin flip."
  • NVO: GLP-1 bridge co-beneficiary alongside Lilly.
  • CVS: formulary reversal on Zepbound (with an ERISA class action behind it) signals weakening PBM exclusion leverage on GLP-1s.

Read-throughs

  • Hospitals (HCA, THC, UHS, DSH systems): 340B is the swing variable, a tighter patient definition or successful data-for-discount coercion erodes a high-margin subsidy. No hospital executives spoke this week, but they are the direct counterparty to the Lilly/AbbVie moves.
  • PBMs / CVS: the Zepbound reversal shows GLP-1 exclusions are politically and legally expensive to hold; formulary power on this class is eroding.
  • GLP-1 exposure (LLY, NVO): bridge demand pull-through is incremental volume; the US-vs-Europe price gap (Williams: charging "70 to 80 percent less... in Europe") remains the MFN pressure point.
  • Biosimilars / generics: the "pill penalty" asymmetry is quietly steering pipelines toward biologics, a long-run negative for the small-molecule generic funnel.
  • Medicaid / exchange insurers (CNC, MOH, ELV): Kelly Munson, CEO of Independence Health Group (operator/insider), warned on Becker's Payer Issues that work requirements churn eligible people off coverage administratively, "92%... of the people who participate in the Medicaid expansion programs work already", and that Georgia and Arkansas precedents saw "thousands of people drop off the rolls." Layer on the enhanced-subsidy sunset and the membership setup is a 2–3 year headwind.
  • Optum-style services / risk coding: the UNH DOJ probe targets exactly the MA diagnosis-intensity engine that services arms monetize, an overhang on the whole risk-adjustment complex.
  • Hospital prior-auth friction: on Monitor Mondays, Dr. Ronald Hirsch (operator/insider) cited OIG data that MA SNF denials are overturned on appeal "99.7%" of the time for UnitedHealthcare, fuel for the "MA is over-denying" narrative that pressures the rate/utilization debate.

What Changed

  • 340B shifted from rhetoric to enforcement: Lilly's ultimatum letters are physically going out, and AbbVie's patient-definition case is now before a federal judge. The count of manufacturers demanding claims data is up to roughly ten.
  • The Medicare GLP-1 bridge goes live in July (running through end of 2027), and CVS Caremark reversed its Zepbound exclusion.
  • Reconciliation 3.0 looks dead this week, multiple sources (DC EKG, Paging America) report no Senate appetite, which removes a near-term legislative vector for fresh drug-pricing or Medicaid changes and pushes the action back to the agencies and the courts.